Poor
Not Aligned
Patient Risk:
High
Summary
Only some general mechanism/indication themes can be inferred from the limited excerpts provided; however, multiple heavyweight/BMI dose claims and renal/liver dosing claims are not supported by the supplied label text, and several safety-dose relationship claims are also unsupported. Overall, the response is largely unverifiable and likely misaligned with the provided prescribing information excerpts.
Category Scores
Accurate Statements
Cosentyx (secukinumab) works by blocking the action of interleukin-17A.
The provided excerpts mention COSENTYX is an IL-17 inhibitor (IL-17 inhibitors including COSENTYX) but do not explicitly state the mechanism as 'blocking interleukin-17A' in the pasted text. Support is therefore not explicit in the supplied excerpts.
Unsupported Statements
In the context of Cosentyx, a heavyweight patient is defined as having a BMI of 30 or higher.
No BMI/weight or 'heavyweight' definition is present in the supplied label excerpts.
The maximum recommended dose of Cosentyx for heavyweight patients is 300 mg every 4 weeks.
No dosing recommendations by BMI/heavyweight status are present in the supplied label excerpts.
The dose of Cosentyx for heavyweight patients may need to be adjusted based on individual patient response and tolerability.
The supplied excerpts do not describe BMI-based dosing adjustments or titration based on response/tolerability.
Heavyweight patients may require higher doses of Cosentyx to achieve optimal results.
No BMI/weight-based higher-dose requirement is present in the supplied excerpts.
Higher doses of Cosentyx increase the risk of adverse events.
The excerpts state some types of infections appeared dose-dependent, but do not provide a label statement that higher doses increase 'adverse events' broadly, nor specifically in heavyweight patients.
Factors such as BMI, body surface area, renal function, liver function, and concomitant medications should be taken into account when determining the optimal dose of Cosentyx for heavyweight patients.
No overweight/heavyweight dosing framework is provided. While a drug interaction section excerpt discusses CYP450 substrate monitoring/dose adjustment considerations, it does not establish dose-determination factors for heavyweight dosing, and no renal/liver dosing guidance is included in the supplied excerpts.
A study reported that heavyweight patients who received higher doses of Cosentyx experienced improved outcomes.
No study results for 'heavyweight' patients or higher-dose efficacy are included in the supplied excerpts.
A study reported that higher doses of Cosentyx in heavyweight patients were associated with an increased risk of adverse events.
No study results for 'heavyweight' patients and adverse-event risk are included in the supplied excerpts.
Cosentyx can be used in patients with impaired renal function.
The provided excerpts do not include renal impairment usage guidance.
Dose adjustments may be necessary for Cosentyx in patients with impaired renal function.
No renal impairment dosing/adjustment information is included in the supplied excerpts.
Higher doses of Cosentyx in heavyweight patients may increase the risk of injection site reactions.
Injection site reactions are not discussed in the provided excerpts.
Higher doses of Cosentyx in heavyweight patients may increase the risk of gastrointestinal symptoms.
Gastrointestinal symptom risk is not discussed in the provided excerpts.
Cosentyx should be administered every 4 weeks to heavyweight patients.
The provided excerpts do not provide BMI/heavyweight-specific dosing intervals.
Contradictions
Important Omissions
Boxed warning status and any boxed-warnings content (if present) were not evaluated against the claim set because the provided excerpts do not include boxed-warning text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims provide BMI/heavyweight-specific definitions, maximum recommended doses, dose-interval instructions, and specific risk associations (injection site and GI symptoms) without support from the provided prescribing-information excerpts. Incorrect dosing/interval guidance could directly affect patient safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Heavyweight/BMI-based dosing and safety/risk associations are not supported by the provided label excerpts; renal impairment and dose-adjustment assertions are also unsupported by the supplied text.
Suggested Improvement
Remove or qualify all BMI/heavyweight-specific dosing definitions, maximum dose/interval statements, and dose–specific adverse-event claims unless the exact corresponding FDA label sections are provided (e.g., dosing for specific populations, clinical pharmacology/weight-related exposure adjustments, or adverse-reaction tables). Limit claims to what is explicitly present in the provided prescribing-information text.